Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Period	Debt/Equity
2020-12-31	0.04
2021-12-31	0.11
2022-12-31	0.12
2023-12-31	0.08
2024-12-31	0.31

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PLRX	$1.35	+3.05%	0.22M
3
4
5

Pliant Therapeutics Inc. (PLRX) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Pliant Therapeutics Inc. Data in Excel

More PLRX Financial Data